Bharat Biotech and GSK announce price reduction for the world's first malaria vaccine to under $5. This move aims to improve access and save thousands of children in malaria-endemic countries.

Jan 9 (Reuters) - Ocugen Inc (OCGN.O) said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States.

Bharat Biotech on Wednesday announced a collaboration with Alopexx Inc for development and commercialisation of the latter's broad-spectrum anti-microbial vaccine in India and other low income ...

GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income nations. The vaccine, leveraging generalised ...

India's Bharat Biotech said on Tuesday its oral cholera vaccine cleared a late-stage trial and that it plans a global launch, aiming to make up to 200 million doses a year amid an expanding ...

Bharat Biotech will take charge of the continued development of altSonflex1-2-3, which encompasses Phase 3 clinical trials, regulatory progress, and large-scale production.

Alopexx received $666,666 from Bharat Biotech for rights to the vaccine candidate in India last year but has largely relied on convertible note agreements with Vlock for money in recent years.

Bharat Biotech has terminated a memorandum of understanding to sell its COVID-19 vaccine Covaxin to Brazil's Precisa Medicamentos, the Indian company said on Friday without disclosing the reason.

With Ocugen’s R&D team and technical capabilities in place, the Company leveraged its network, and in 2021 licensed COVAXIN™ from Bharat Biotech for North American Markets.

(Reuters) -Ocugen Inc said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd met the main goals of a trial in the United States. The vaccine, sold ...

GSK Licenses Shigella Vaccine Candidate to Bharat Biotech Published: June 12, 2025, 4:48 a.m. ET Share Resize ...